Holdings
Franklin Genomic Advancements ETF
As of Jun 30, 2026, Franklin Genomic Advancements ETF reported 59 positions worth US$27M. Largest: Guardant Health, Inc., Natera, Inc. and Krystal Biotech, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Guardant Health, Inc. | 16,927 | US$2.54M | +1,209 | Jun 30, 2026 |
| Natera, Inc. | 7,679 | US$2.08M | +548 | Jun 30, 2026 |
| Krystal Biotech, Inc. | 4,757 | US$1.77M | +339 | Jun 30, 2026 |
| Ligand Pharmaceuticals Incorporated | 4,085 | US$1.29M | +291 | Jun 30, 2026 |
| Adaptive Biotechnologies Corporation | 51,956 | US$1.11M | +3,711 | Jun 30, 2026 |
| United Therapeutics Corporation | 1,809 | US$980K | +129 | Jun 30, 2026 |
| Bridgebio Pharma, Inc. | 13,129 | US$978K | +937 | Jun 30, 2026 |
| Eli Lilly And Company | 688 | US$825K | +95 | Jun 30, 2026 |
| Twist Bioscience Corporation | 7,736 | US$796K | +552 | Jun 30, 2026 |
| Vertex Pharmaceuticals Incorporated | 1,545 | US$767K | +110 | Jun 30, 2026 |